Hoa Le
Hoa Le has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Uyen Pham
University of Economics and Law
2 shared publications - Aaron Crowley
Cardiovascular Research Foundation, New York, NY, USA
1 shared publication Anu Santhanagopal
Daiichi Sankyo, Inc, Basking Ridge, USA
1 shared publication- Camryn Lieb
Genesis Research Group, Hoboken, USA
1 shared publication Chuntao Wu
Daiichi Sankyo, Inc, Basking Ridge, USA
1 shared publicationDavid Sternberg
Daiichi Sankyo, Inc, Basking Ridge, USA
1 shared publication
Latest Publications
- Open Access
- 3 July 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (8) , 3299-3315
Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy
Introduction For patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after osimertinib and platinum-based chemotherapy (PBC), no uniformly accepted standard of care exists. Moreover, limited efficacy of standard treatments indicates an unmet medical need, which is being addressed by ongoing clinical investigations, including the HERTHENA-Lung01 (NCT04619004) study of patritumab deruxtecan (HER3‑DXd). However, because limited information is available on real-world clinical outcomes in such patients, early-phase trials of investigational therapies lack sufficient context for comparison. This study describes the real-world clinical characteristics, treatments, and outcomes for patients with EGFRm mNSCLC who initiated a new line of therapy following previous osimertinib and PBC, including a subset matched to the HERTHENA-Lung01 population. Methods This retrospective analysis used a US database derived from deidentified electronic health records. The reference cohort included patients with EGFRm mNSCLC who had initiated a new line of therapy between November 13, 2015 and June 30, 2021, following prior osimertinib and PBC. A subset of patients resembling the HERTHENA-Lung01 population was then extracted from the reference cohort; this matched subset was optimized using propensity score (PS) weighting. Endpoints were real-world overall survival (rwOS) and real-world progression-free survival (rwPFS). Confirmed real-world objective response rate (rwORR; partial/complete response confirmed ≥ 28 days later) was calculated for the response-evaluable subgroups of patients (with ≥ 2 response assessments spaced ≥ 28 days apart). Results In the reference cohort (N = 273), multiple treatment regimens were used, and none was predominant. Median rwPFS and rwOS were 3.3 and 8.6 months, respectively; confirmed rwORR (response evaluable, n = 123) was 13.0%. In the matched subset (n = 126), after PS weighting, median rwPFS and rwOS were 4.2 and 9.1 months, respectively; confirmed rwORR (response evaluable, n = 57) was 14.1%. Conclusion The treatment landscape for this heavily pretreated population of patients with EGFRm mNSCLC is fragmented, with no uniformly accepted standard of care. A high unmet need exists for therapeutic options that provide meaningful improvements in clinical benefit.
- 3 July 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (8) , 3299-3315
Open AccessReal-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy
Introduction For patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after osimertinib and platinum-based chemotherapy (PBC), no uniformly accepted standard of care exists. Moreover, limited efficacy of standard treatments indicates an unmet medical need, which is being addressed by ongoing clinical investigations, including the HERTHENA-Lung01 (NCT04619004) study of patritumab deruxtecan (HER3‑DXd). However, because limited information is available on real-world clinical outcomes in such patients, early-phase trials of investigational therapies lack sufficient context for comparison. This study describes the real-world clinical characteristics, treatments, and outcomes for patients with EGFRm mNSCLC who initiated a new line of therapy following previous osimertinib and PBC, including a subset matched to the HERTHENA-Lung01 population. Methods This retrospective analysis used a US database derived from deidentified electronic health records. The reference cohort included patients with EGFRm mNSCLC who had initiated a new line of therapy between November 13, 2015 and June 30, 2021, following prior osimertinib and PBC. A subset of patients resembling the HERTHENA-Lung01 population was then extracted from the reference cohort; this matched subset was optimized using propensity score (PS) weighting. Endpoints were real-world overall survival (rwOS) and real-world progression-free survival (rwPFS). Confirmed real-world objective response rate (rwORR; partial/complete response confirmed ≥ 28 days later) was calculated for the response-evaluable subgroups of patients (with ≥ 2 response assessments spaced ≥ 28 days apart). Results In the reference cohort (N = 273), multiple treatment regimens were used, and none was predominant. Median rwPFS and rwOS were 3.3 and 8.6 months, respectively; confirmed rwORR (response evaluable, n = 123) was 13.0%. In the matched subset (n = 126), after PS weighting, median rwPFS and rwOS were 4.2 and 9.1 months, respectively; confirmed rwORR (response evaluable, n = 57) was 14.1%. Conclusion The treatment landscape for this heavily pretreated population of patients with EGFRm mNSCLC is fragmented, with no uniformly accepted standard of care. A high unmet need exists for therapeutic options that provide meaningful improvements in clinical benefit.
- 17 November 2018
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 49 (8) , 2164-2180
Improvement on Monte Carlo estimation of HPD intervals
In Bayesian statistics, there have been several methods on estimating the highest probability posterior density (HPD) such as using Monte Carlo approach combined with mean relative error (ME) served as a measure of effectiveness in Chen and Shao ( 1999 Chen, M. H. , and Q. M. Shao. 1999. Monte Carlo estimation of Bayesian credible and HPD intervals. Journal of Computational and Graphical Statistics 8 (1):69–92. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ) and Chen, Shao and Ibrahim ( 2012 Chen, M. H. , Q. M. Shao, and J. G. Ibrahim. 2012. Monte Carlo methods in Bayesian computation. Berlin: Springer Science & Business Media. [Google Scholar] ) for the unimodal case and a simple application to Bayesian hierarchical model. In this paper, we firstly reconsider the former and then propose a new method based on probability density function with an algorithm in order to give an estimation for HPD intervals to improve on Monte Carlo in both unimodal and multimodal cases. We further show that our new method has made an improvement in producing credible intervals with the shortest length for some cases. The necessary theory is developed and illustrative examples are provided.
- 17 November 2018
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 49 (8) , 2164-2180
Improvement on Monte Carlo estimation of HPD intervals
In Bayesian statistics, there have been several methods on estimating the highest probability posterior density (HPD) such as using Monte Carlo approach combined with mean relative error (ME) served as a measure of effectiveness in Chen and Shao ( 1999 Chen, M. H. , and Q. M. Shao. 1999. Monte Carlo estimation of Bayesian credible and HPD intervals. Journal of Computational and Graphical Statistics 8 (1):69–92. [Taylor & Francis Online], [Web of Science ®] , [Google Scholar] ) and Chen, Shao and Ibrahim ( 2012 Chen, M. H. , Q. M. Shao, and J. G. Ibrahim. 2012. Monte Carlo methods in Bayesian computation. Berlin: Springer Science & Business Media. [Google Scholar] ) for the unimodal case and a simple application to Bayesian hierarchical model. In this paper, we firstly reconsider the former and then propose a new method based on probability density function with an algorithm in order to give an estimation for HPD intervals to improve on Monte Carlo in both unimodal and multimodal cases. We further show that our new method has made an improvement in producing credible intervals with the shortest length for some cases. The necessary theory is developed and illustrative examples are provided.
- Open Access
- 30 November 2017
- Published by Viet Nam National University Ho Chi Minh City in Science & Technology Development Journal: Economics- Law & Management
- Vol. 1 (Q2) , 144-155
Choosing the best model in fuzzy Bayesian statistics and its application in financial analysis
Analysts generally use closing price and normal distribution assumption for a model’s distribution in financial analysis. However, stock price fluctuation is reflected by a set of four values, namely opening, highest, lowest and closing prices. We therefore include the highest and the lowest prices to take into account more information in the hope of ending up with a more exact result as data contains a ranges of values instead of one only (i.e. the data is a form of fuzzy number). Moreover, the assumption that data is normally distributed is not always satisfied and Jacque Bera or Chi square tests are often employed to test the data’s normality. The tests require the use of pvalue which is quite controversial at present. This paper employs fuzzy Bayes point estimator to choose the most suitable distribution. On a sample of 9 stocks with large capitalization in Vietnam from their listed dates until November 06, 2015, we found that some stocks have prices distributed more reasonably than normal distribution and some are not.
- 30 November 2017
- Published by Viet Nam National University Ho Chi Minh City in Science & Technology Development Journal: Economics- Law & Management
- Vol. 1 (Q2) , 144-155
Open AccessChoosing the best model in fuzzy Bayesian statistics and its application in financial analysis
Analysts generally use closing price and normal distribution assumption for a model’s distribution in financial analysis. However, stock price fluctuation is reflected by a set of four values, namely opening, highest, lowest and closing prices. We therefore include the highest and the lowest prices to take into account more information in the hope of ending up with a more exact result as data contains a ranges of values instead of one only (i.e. the data is a form of fuzzy number). Moreover, the assumption that data is normally distributed is not always satisfied and Jacque Bera or Chi square tests are often employed to test the data’s normality. The tests require the use of pvalue which is quite controversial at present. This paper employs fuzzy Bayes point estimator to choose the most suitable distribution. On a sample of 9 stocks with large capitalization in Vietnam from their listed dates until November 06, 2015, we found that some stocks have prices distributed more reasonably than normal distribution and some are not.
- 13 February 2017
- Published by Springer Nature
- p. 305-319
An Alternative to p-Values in Hypothesis Testing with Applications in Model Selection of Stock Price Data
- 13 February 2017
- Published by Springer Nature
- p. 305-319
An Alternative to p-Values in Hypothesis Testing with Applications in Model Selection of Stock Price Data
- 1 January 2015
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 157-162
A new pre-authentication protocol in Kerberos 5: biometric authentication
Kerberos is a well-known network authentication protocol that allows nodes to communicate over a non-secure network connection. After Kerberos is used to prove the identity of objects in client-server model, it will encrypt all of their communications in following steps to assure privacy and data integrity. In this paper, we modify the initial authentication exchange in Kerberos 5 by using biometric data and asymmetric cryptography. This proposed method creates a new preauthentication protocol in order to make Kerberos 5 more secure. Due to the proposed method, the limitation of password-based authentication in Kerberos 5 is solved. It is too difficult for a user to repudiate having accessed to the application. Moreover, the mechanism of user authentication is more convenient. This method is a strong authentication scheme that is against several attacks.
- 1 January 2015
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 157-162
A new pre-authentication protocol in Kerberos 5: biometric authentication
Kerberos is a well-known network authentication protocol that allows nodes to communicate over a non-secure network connection. After Kerberos is used to prove the identity of objects in client-server model, it will encrypt all of their communications in following steps to assure privacy and data integrity. In this paper, we modify the initial authentication exchange in Kerberos 5 by using biometric data and asymmetric cryptography. This proposed method creates a new preauthentication protocol in order to make Kerberos 5 more secure. Due to the proposed method, the limitation of password-based authentication in Kerberos 5 is solved. It is too difficult for a user to repudiate having accessed to the application. Moreover, the mechanism of user authentication is more convenient. This method is a strong authentication scheme that is against several attacks.